Shifting Mindsets: Practice Assessment

This section contains a baseline assessment of current practice in the management and treatment of dyslipidemia patients and is required to be completed once. Once you have answered all questions, click the “next” button at the bottom of the page. Should there be any errors or questions missed, the portal will alert you prior to being able to move on to the next section.

Disclosures

Jeff Habert, MD, CCFP, FCFP

Speaker / Consultant / Scientific Planning Committee: MDBriefcase, Liv, MedPlan, Brandaide, Master Clinician Alliance, Academy, Bridge, Thrombosis Canada, Meducom, Antibody, CHRC, CTC, STA, CCRN, imc, ICPDHM, Four Health Comm, CPD Network, Telus Health, EOCI

Advisory Board / Speaker Bureaus: Pfizer, Amgen, BMS, Bayer, Boehringer, Eli-Lilly, Purdue, Bausch, Allergan, Mylan, Astra-Zeneca, Novartis, Lundbeck, Novo-Nordisk, Servier, Janssen, Eisai, HLS, Otsuka, Sunovion

Disclosures

Shaun Goodman, MD, MSc, FRCPC, FACC, FAHA, FESC, FCCS

Scientific Planning Committee: CPD Network

Advisory Board / Speaker Bureaus: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Eli Lilly, Ferring Pharmaceuticals, HLS Therapeutics, JAMP Pharma, Janssen/Johnson & Johnson, Merck, Novartis, Pendopharm, Pfizer, Regeneron, Sanofi, Servier, Valeo Pharma

Funding Grants / Research / Clinical Trials: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Daiichi-Sankyo/American Regent, Eli Lilly, Esperion, Ferring Pharmaceuticals, GlaxoSmithKline, HLS Therapeutics, JAMP Pharma, Janssen/Johnson & Johnson, Merck, Novartis, Novo Nordisk A/C, Pendopharm, Pfizer, Regeneron, Sanofi, Servier, Valeo Pharma

Other: Heart and Stroke Foundation of Ontario/University of Toronto (Polo) Chair, Canadian Heart Research Centre and MD Primer, Canadian VIGOUR Centre, Cleveland Clinic Coordinating Centre for Clinical Research, Duke Clinical Research Institute, New York University Clinical Coordinating Centre, and PERFUSE Research Institute

Disclosures

Patricia Froese, MD, CCFP

Scientific Planning Committee: CPD Network

Disclosures

Elissa Weinberg, MD, CCFP, FCFP

Scientific Planning Committee: Academy, Bridge Medical Communications, CPD Network, Integrated Medhealth Communications, LIV, and MedPlan

MainProPA Main Banner

Please review the patient case and provide your response to the following question:

Patient Profile

61-year-old male, smoker

  • Post- anterior MI
  • LAD was stented
  • LVEF – 57%

Medical History

  • Overweight (BMI – 30)
  • LDL-C – 2.0 mmol/L

Prior to the MI, patient was taking: atorvastatin 80 mg PO daily

(1 — not familiar to 5 — very familiar)

cpdisup